

WPS GHA
J8 Contractor Advisory Committee Meeting
Moderator: Noel, Dr. Ella
February 24, 2020
06:00 PM ET

OPERATOR: This is Conference # 9382285

Operator: Ladies and gentlemen, thank you for standing by and welcome to the J8 MAC Advisory Committee Meeting. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session.

To ask a question during this session, you will need to press star one on your telephone keypad. Please be advised that today's conference is being recorded. And if you require any further assistance, please press star zero.

I would now like to hand the call over to your speaker for today, Dr. Ella Noel, you may begin your conference.

Dr. Ella Noel: Thank you. I'd like to welcome everybody to the J8 contractor advisory committee meeting tonight. Hopefully, you have a good connection and you can hear well. I am the J8 contractor medical director and I'm joined on the phone by other WPS staff, Mary Muchow from provider outreach and education; Ann Everson, from policy, Melissa Lietz from policy. Did I miss anybody else from WPS that's on the line?

Maria, did anybody else I need to introduce themselves from WPS?

Operator: And all lines are now open.

Dr. Ella Noel: Okay. This is a reminder before we talk about the two drafts tonight. This is no longer a closed meeting. It will be followed by a closed educational meeting. Continued participation on this call indicates your consent for identification in any discussions about the draft policies presented during this meeting tonight. Please follow up any verbal comment with written comments that Medicarepolicycomments@wpsic.com.

The comment period last for a total of 45 days once the draft policy is posted and ends on March 15th, 2020. We have 2 drafts today. We'll start with the first one. It is DL38530. This is a molecular diagnostic policy and the CMD for this draft and along with that is policy coordinator Beth Scanlon. It's called Circulating Tumor Cell Marker Assays.

This is a non-coverage policy for all circulating tumor cell marker assays. There is currently no data to demonstrate improved, patient outcomes or that the assays results and changes in physician management.

Maria, do we have any comments on the phone about this draft.

Operator: And if you would like to have the comments, you need to press star one on your telephone keypad. We have a comment coming from the line of Robert Kettler. Your line is open.

Dr. Robert Kettler: Thank you. I don't have anything to add to that LCD.

Dr. Ella Noel: Thank you. Do we have any other comments, Maria?

Operator: No other comments ma'am.

Dr. Ella Noel: And just for everyone's information, I am the only person here at the meeting. So, I will not be asking for comments from the room. Next draft, DL38528, Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea. Our CMD, Ryan Holzmacher, is the physician on this policy along with policy coordinator Ann Everson.

This is a limited coverage policy for FDA approved hypoglossal nerve stimulators for moderate-to-severe obstructive sleep apnea when all of the following parameters are met. The beneficiary is 22-years of age or older. The BMI is less than 35. Polysomnography is performed within 24- months of first consultation for hypoglossal neurostimulator. It is predominantly obstructive event. Documentation must demonstrate CPAP failure or intolerance.

There needs to be absence of complete concentric collapse at the soft palate level as seen on drug induced sleep endoscopy procedures and no findings that would compromise the performance of the device. Do we have any comments on the phone?

Operator: And if you would like to have a comment, you need to press star one on your telephone keypad.

We have a comment coming from the line of Christopher Wilson.

Dr. Ella Noel: Please go ahead.

Christopher Wilson: Hi, it's Neurology and Sleep Medicine from Indiana and I think those LCD makes a lot of sense. Commercial payers have covered it for a few years now, maybe 5 or 6. And it's rarely used that probably good adjunct or like third- or fourth-line therapy kind of stuff. So I'm glad to see it's covered. So, I would be in favor of this.

Dr. Ella Noel: Well, thank you. Any other comments on the draft?

Operator: And we don't have additional comments ma'am.

Dr. Ella Noel: Okay, Maria. I'll go ahead and conclude the open portion of the meeting. Those who were on the line that were to listen in and make no comments can be released, then we'll go to our close educational portion of the meeting.

Operator: Okay ma'am.